These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33710118)

  • 21. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
    Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
    J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
    Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
    Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An enhancer haplotype may influence BCL11A expression levels and the response to hydroxyurea in β-thalassemia patients.
    Maroofi N; Azarkeivan A; Banihashemi S; Mohammadparast S; Aghajanirefah A; Banan M
    Pharmacogenomics; 2017 Jul; 18(10):995-967. PubMed ID: 28639471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: A study on β-thalassemia and hemoglobin E/β-thalassemia patients in Indonesia.
    Rujito L; Basalamah M; Siswandari W; Setyono J; Wulandari G; Mulatsih S; Sofro AS; Sadewa AH; Sutaryo S
    Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):55-63. PubMed ID: 27009595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
    Karimi M; Zarei T; Bahmanimehr A; Aramesh A; Daryanoush S; Haghpanah S
    Ann Hematol; 2021 Dec; 100(12):2901-2907. PubMed ID: 34383102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern.
    Iqbal A; Ansari SH; Parveen S; Khan IA; Siddiqui AJ; Musharraf SG
    Sci Rep; 2018 Oct; 8(1):15152. PubMed ID: 30310134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
    Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
    Ansari SH; Shamsi TS; Ashraf M; Perveen K; Farzana T; Bohray M; Erum S; Mehboob T
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):339-43. PubMed ID: 21602718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
    Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
    Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
    Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
    Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
    [No Abstract]   [Full Text] [Related]  

  • 32. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
    Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):116-125. PubMed ID: 28408107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression.
    Huang SZ; Ren ZR; Chen MJ; Xu HP; Zeng YT; Rodgers GP; Zeng FY; Schechter AN
    Sci China B; 1994 Nov; 37(11):1350-9. PubMed ID: 7865126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia.
    Hoppe C; Vichinsky E; Lewis B; Foote D; Styles L
    Am J Hematol; 1999 Dec; 62(4):221-7. PubMed ID: 10589077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
    Bohara VV; Ray S; Chakrabarti P; Ray SS; Nath UK; Chaudhuri U
    Hemoglobin; 2014; 38(1):44-8. PubMed ID: 24144212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
    Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
    Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
    Banan M
    Ann Hematol; 2013 Mar; 92(3):289-99. PubMed ID: 23318979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease.
    Badens C; Joly P; Agouti I; Thuret I; Gonnet K; Fattoum S; Francina A; Simeoni MC; Loundou A; Pissard S
    Haematologica; 2011 Nov; 96(11):1712-4. PubMed ID: 21791466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
    Tafrali C; Paizi A; Borg J; Radmilovic M; Bartsakoulia M; Giannopoulou E; Giannakopoulou O; Stojiljkovic-Petrovic M; Zukic B; Poulas K; Stavrou EF; Lambropoulou P; Kourakli A; Felice AE; Papachatzopoulou A; Philipsen S; Pavlovic S; Georgitsi M; Patrinos GP
    Pharmacogenomics; 2013 Apr; 14(5):469-83. PubMed ID: 23556445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.